USD 0.65
(-0.78%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.33 Million USD | -67.79% |
2022 | 4.12 Million USD | -16.89% |
2021 | 4.96 Million USD | 52.39% |
2020 | 3.26 Million USD | 2.03% |
2019 | 3.19 Million USD | 32.79% |
2018 | 2.4 Million USD | 20.24% |
2017 | 2 Million USD | 5.99% |
2016 | 1.88 Million USD | -28.75% |
2015 | 2.65 Million USD | -52.32% |
2014 | 5.55 Million USD | 32.84% |
2013 | 4.18 Million USD | 24.26% |
2012 | 3.36 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 FY | 1.33 Million USD | -67.79% |
2023 Q2 | 3.53 Million USD | -17.58% |
2023 Q4 | 1.33 Million USD | -18.65% |
2023 Q1 | 4.28 Million USD | 3.88% |
2023 Q3 | 1.63 Million USD | -53.75% |
2022 Q2 | 4.7 Million USD | -16.53% |
2022 Q3 | 4.62 Million USD | -1.7% |
2022 Q4 | 4.12 Million USD | -10.67% |
2022 FY | 4.12 Million USD | -16.89% |
2022 Q1 | 5.63 Million USD | 13.39% |
2021 Q1 | 4.42 Million USD | 35.58% |
2021 FY | 4.96 Million USD | 52.39% |
2021 Q3 | 4.63 Million USD | 6.38% |
2021 Q4 | 4.96 Million USD | 7.21% |
2021 Q2 | 4.35 Million USD | -1.45% |
2020 FY | 3.26 Million USD | 2.03% |
2020 Q1 | 2.93 Million USD | -8.01% |
2020 Q2 | 2.87 Million USD | -2.21% |
2020 Q3 | 2.98 Million USD | 4.0% |
2020 Q4 | 3.26 Million USD | 9.07% |
2019 Q1 | 1.8 Million USD | -25.19% |
2019 FY | 3.19 Million USD | 32.79% |
2019 Q4 | 3.19 Million USD | 8.56% |
2019 Q3 | 2.94 Million USD | 11.9% |
2019 Q2 | 2.63 Million USD | 46.11% |
2018 Q4 | 2.4 Million USD | -6.02% |
2018 Q2 | 2.25 Million USD | 4.15% |
2018 Q1 | 2.16 Million USD | 8.4% |
2018 FY | 2.4 Million USD | 20.24% |
2018 Q3 | 2.56 Million USD | 13.32% |
2017 FY | 2 Million USD | 5.99% |
2017 Q2 | 2.47 Million USD | 7.34% |
2017 Q3 | 2.22 Million USD | -10.04% |
2017 Q1 | 2.3 Million USD | 21.88% |
2017 Q4 | 2 Million USD | -9.95% |
2016 Q2 | 2 Million USD | -17.43% |
2016 FY | 1.88 Million USD | -28.75% |
2016 Q4 | 1.88 Million USD | 1.07% |
2016 Q3 | 1.86 Million USD | -7.02% |
2016 Q1 | 2.43 Million USD | -8.19% |
2015 Q2 | 10.63 Million USD | 149.98% |
2015 Q1 | 4.25 Million USD | -23.43% |
2015 FY | 2.65 Million USD | -52.32% |
2015 Q4 | 2.65 Million USD | -65.84% |
2015 Q3 | 7.75 Million USD | -27.09% |
2014 Q1 | - USD | -100.0% |
2014 FY | 5.55 Million USD | 32.84% |
2014 Q2 | 4.24 Million USD | 0.0% |
2014 Q4 | 5.55 Million USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 FY | 4.18 Million USD | 24.26% |
2013 Q3 | 1.02 Million USD | 0.0% |
2013 Q4 | 1.02 Million USD | 0.0% |
2012 FY | 3.36 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Biodesix, Inc. | 94.51 Million USD | 98.593% |
Castle Biosciences, Inc. | 86.54 Million USD | 98.463% |
Exact Sciences Corporation | 3.32 Billion USD | 99.96% |
IDEXX Laboratories, Inc. | 1.77 Billion USD | 99.925% |
23andMe Holding Co. | 206.64 Million USD | 99.356% |
NeoGenomics, Inc. | 739.69 Million USD | 99.82% |
Neogen Corporation | 1.44 Billion USD | 99.908% |
Inotiv, Inc. | 588.04 Million USD | 99.774% |
Psychemedics Corporation | 6.59 Million USD | 79.842% |
RadNet, Inc. | 2.07 Billion USD | 99.936% |
Star Equity Holdings, Inc. | 21.67 Million USD | 93.864% |
bioAffinity Technologies, Inc. | 3.36 Million USD | 60.491% |
Illumina, Inc. | 4.36 Billion USD | 99.97% |
Aspira Women's Health Inc. | 8.62 Million USD | 84.583% |
Prenetics Global Limited | 44.01 Million USD | 96.978% |
iSpecimen Inc. | 6.07 Million USD | 78.118% |
OpGen, Inc. | 13.44 Million USD | 90.107% |
T2 Biosystems, Inc. | 62.83 Million USD | 97.883% |
Standard BioTools Inc. | 159.86 Million USD | 99.168% |
Neuronetics, Inc. | 81.64 Million USD | 98.371% |
Precipio, Inc. | 3.67 Million USD | 63.78% |
Intelligent Bio Solutions Inc. | 5.59 Million USD | 76.232% |
Exagen Inc. | 34.25 Million USD | 96.117% |
Bionano Genomics, Inc. | 118.24 Million USD | 98.875% |
CareDx, Inc | 223.28 Million USD | 99.404% |
Twist Bioscience Corporation | 152.97 Million USD | 99.131% |
Guardant Health, Inc. | 1.62 Billion USD | 99.918% |
BioNexus Gene Lab Corp. | 1.74 Million USD | 23.648% |
Natera, Inc. | 691.79 Million USD | 99.808% |
Fulgent Genetics, Inc. | 139.82 Million USD | 99.049% |
Sera Prognostics, Inc. | 25.28 Million USD | 94.74% |
OPKO Health, Inc. | 622.47 Million USD | 99.786% |
Personalis, Inc. | 95.65 Million USD | 98.61% |
Aclaris Therapeutics, Inc. | 40.22 Million USD | 96.694% |
Applied DNA Sciences, Inc. | 8.77 Million USD | 84.85% |
Myriad Genetics, Inc. | 312.9 Million USD | 99.575% |
ICON Public Limited Company | 7.74 Billion USD | 99.983% |
Star Equity Holdings, Inc. | 21.67 Million USD | 93.864% |
MDxHealth SA | 121.92 Million USD | 98.909% |
Prenetics Global Limited | 44.01 Million USD | 96.978% |
DarioHealth Corp. | 38.24 Million USD | 96.522% |
ENDRA Life Sciences Inc. | 1.09 Million USD | -21.444% |
Medpace Holdings, Inc. | 1.09 Billion USD | 99.879% |
Mainz Biomed B.V. | 12.15 Million USD | 89.062% |
Trinity Biotech plc | 83.38 Million USD | 98.405% |
Sotera Health Company | 2.68 Billion USD | 99.95% |
bioAffinity Technologies, Inc. | 3.36 Million USD | 60.491% |